10 Best Organ Transplant and Diagnosis Stocks To Buy Now

7. Novartis AG (NYSE:NVS)

Market Cap as of August 1: $227.25 Billion

Hedge Funds Holding Stakes: 30

Novartis AG (NYSE:NVS) is one of the 10 best organ transplant and diagnosis stocks to buy now as it develops pharmaceuticals, including immunosuppressant drugs, to prevent organ rejection in transplant patients. Its portfolio includes drugs for kidney, liver, and heart transplants.

Novartis AG (NYSE:NVS) is already up by 10% for the year, generating $11.8 billion in sales in 2023, up 12% year over year. According to the Insider Monkey database, the number of hedge funds holding stakes in Novartis AG (NYSE:NVS) increased to 30 in Q1 2024 from 28 as of the fourth quarter of 2023.

In its Q2 2024 investor letter, Aristotle Capital International Equity Strategy commented on Novartis AG (NYSE:NVS) as follows:

“We have been investors in the Swiss pharmaceutical company Novartis AG (NYSE:NVS) for over a decade, having first purchased shares in 2011. During our holding period, the company has undergone significant changes. Vacant (“Vas”) Narasimhan was promoted to CEO in 2018 and, we believe, has positively influenced the company’s culture and helped shift the business more toward innovative medicines. Examples include the sale of Novartis’s consumer (over-the-counter) joint venture; the divestiture of its vaccines and animal health businesses; the spinoff of Alcon, a global leader in the treatment of eye diseases and eye conditions (also an International Equity holding); and most recently, the spinoff of generics manufacturer Sandoz. As part of its portfolio transformation, Novartis has been able to improve its margins and gain share of branded pharmaceuticals. With many catalysts having neared completion, we decided to sell Novartis to fund the purchase of what we believe is a more optimal investment in Roche.”